“Old is gold” hydralazine, a magic bullet for dry eye disease

Clicks: 11
ID: 334134
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #46 of 48 articles by views in The Journal of Biochemistry

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Dry eye disease (DED) is a highly prevalent ocular condition characterized by insufficient tear production or poor tear quality, leading to inflammation, discomfort, and potential vision impairment. Current treatments, primarily artificial tears and limited prescription options like steroids, often provide only partial or temporary relief, underscoring the critical need for more effective and safer therapeutic strategies. A key pathological driver of DED is oxidative stress, which generates reactive aldehyde species (RASP) like malondialdehyde and 4-HNE. These cytotoxic electrophiles form adducts with cellular macromolecules, causing widespread damage. This work explores a therapeutic approach focused on scavenging RASP to mitigate this damage. Inspired by the known carbonyl-scavenging ability of the hydrazide group, we found hydralazine, an anti-hypertensive drug that contains highly nucleophilic hydrazide group can react rapidly with aldehydes to form stable, non-toxic products. This compound is engineered to be potent scavengers of RASP, offering a promising new avenue for the treatment of Dry Eye Disease by directly targeting a root cause of oxidative cellular damage.
Reference Key
openalex_W7223650464 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Biao Ma, Muhammad Ikram Anwar, Leiming Wang, Jinying Qiu, Weijun Shen
Are you one of these authors? Claim your profile
Journal The Journal of Biochemistry
Year 2026
DOI
10.1093/jb/mvag072
URL
https://doi.org/10.1093/jb/mvag072
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.